What is the current valuation of Chinook Therapeutics’s Atrasentan Hydrochloride
Atrasentan Hydrochloride is a small molecule commercialized by Chinook Therapeutics, with a leading Phase III program in IgA Nephropathy (Berger’s Disease). According to Globaldata, it is involved in 24 clinical trials, of which 19 were completed, 2 are ongoing, 1 is planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Atrasentan Hydrochloride’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Atrasentan Hydrochloride is expected to reach an annual total of $104 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Atrasentan Hydrochloride Overview
Atrasentan hydrochloride (ABT-627) is under development for the treatment of immunoglobulin A nephropathy and proteinuric glomerular diseases including focal segmental glomerulosclerosis (FSGS), alport syndrome and diabetic kidney disease (DKD). The drug candidate is administered orally. The drug candidate selectively targets endothelin-A receptor. It was also under development for the treatment of diabetic nephropathy associated with chronic kidney disease, pediatric nephrotic syndrome, metastatic hormone-refractory prostate cancer, hypertension, diabetic neuropathic pain and ovarian cancer
Chinook Therapeutics Overview
Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators; and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products are under development and are intended for the treatment of variety of cancers, including metastatic colorectal, multiple myeloma cancers, as well as other solid tumors and lymphomas. The company collaborates with various pharmaceutical companies to expand its products, and technology platforms. It has an operational presence in The Netherlands. Chinook is headquartered in Berkeley, California, the US.
The company reported revenues of (US Dollars) US$51.6 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$0.8 million in FY2020. The operating loss of the company was US$99 million in FY2021, compared to an operating loss of US$83.9 million in FY2020. The net loss of the company was US$102.9 million in FY2021, compared to a net loss of US$81.6 million in FY2020.
The company reported revenues of US$2.5 million for the third quarter ended September 2022, compared to a revenue of US$0.4 million the previous quarter.
For a complete picture of Atrasentan Hydrochloride’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
#current #valuation #Chinook #Therapeuticss #Atrasentan #Hydrochloride